Pharmacokinetics and Safety of Ebastine in Healthy Subjects and Patients with Renal Impairment

被引:0
作者
Robert J. Noveck
Richard A. Preston
Suzanne K. Swan
机构
[1] MDS Pharma Services,
[2] University of Miami,undefined
[3] Hennepin County Medical Center and Davita Clinical Research,undefined
来源
Clinical Pharmacokinetics | 2007年 / 46卷
关键词
Renal Impairment; Allergic Rhinitis; Normal Renal Function; Severe Renal Impairment; Ebastine;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:525 / 534
页数:9
相关论文
共 31 条
[1]  
Vincent J.(1988)The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects Br J Clin Pharmacol 26 497-502
[2]  
Liminana R.(1992)Pharmacokinetic studies of ebastine in rats, dogs and man Drugs Today (Barc) 28 57-67
[3]  
Meredith P.A.(1994)Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects Arzneimittelforschung 44 59-64
[4]  
Martinez-Tobed A.(1998)N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450 Drug Metab Dispos 26 566-71
[5]  
Tarruús E.(1993)Comparative pharmacokinetics of carebastine/ebastine in moderately renally impaired and healthy volunteers following a single 10mg dose of ebastine: PPDM-8370 [abstract] Pharm Res 10 S390-52
[6]  
Segura J.(1996)Cardiac actions of antihistamines Annu Rev Pharmacol Toxicol 36 233-8
[7]  
Yamaguchi T.(1999)H1-receptor antagonists: safety issues Ann Allergy Asthma Immunol 83 481-401
[8]  
Hashizume T.(1999)Comparative tolerability of second generation antihistamines Drug Saf 20 385-20
[9]  
Matsuda M.(2001)Problems of heart rate correction in assessment of drug-induced QT interval prolongation J Cardiovasc Electrophysiol 12 411-54
[10]  
Hashizume T.(2005)Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects Br J Clin Pharmacol. 59 346-3